This program is studying pravibismane, a new inhaled antibiotic. In the lungs of people with CF, bacteria may form protective layers -- known as biofilms -- that make them more difficult to kill. Pravibismane may help break down biofilms and kill drug-resistant bacteria, such as multi-drug resistant Pseudomonas aeruginosa.

Status

This program is no longer being studied in CF.

Sponsor

This program was sponsored by Microbion and partially funded by the Cystic Fibrosis Foundation.